#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	11046	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2116	515.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1396	1396	C	629	C	611	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19726	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3422	571.1	0	.	n	.	0	A20C	SNP	20	20	A	272	272	C	362	C,A	357,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19726	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3422	571.1	0	.	n	.	0	T695C	SNP	695	695	T	947	947	C	594	C	584	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19726	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3422	571.1	0	.	n	.	0	A1638G	SNP	1638	1638	A	1890	1890	G	611	G,A,C	598,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19726	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3422	571.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2223	2223	C	638	C,A	625,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19726	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3422	571.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2297	2297	A	688	A	675	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19726	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3422	571.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2849	2849	C	610	C	598	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1514	folP	855	855	100.0	folP.l15.c4.ctg.1	1504	100.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1026	1028	AGC	153;157;157	A;G;C	151;156;153	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4172	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3543	117.0	1	SNP	p	S91F	1	.	.	271	273	TTC	672	674	TTC	149;149;152	T;T;C,T	146;146;146,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4172	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3543	117.0	1	SNP	p	G95N	0	.	.	283	285	GGC	684	686	GGC	138;136;136	G;G;C	133;133;134	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4172	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3543	117.0	1	SNP	p	D95G	1	.	.	283	285	GGC	684	686	GGC	138;136;136	G;G;C	133;133;134	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1192	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1395	85.0	0	.	p	.	0	F184L	NONSYN	550	552	TTC	870	872	TTG	124;123;121	T;T;G	122;121;120	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1192	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1395	85.0	1	SNP	p	G45D	0	.	.	133	135	GGC	453	455	GGC	159;156;156	G;G;C,T	159;156;154,1	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	660	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	975	66.9	0	.	n	.	0	A197.	DEL	197	197	A	583	583	A	129	A	126	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3526	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2947	118.5	1	SNP	p	D86N	0	.	.	256	258	GAC	586	588	GAC	128;128;129	G;A;C	124;123;126	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3526	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2947	118.5	1	SNP	p	S87R	1	.	.	259	261	CGT	589	591	CGT	130;130;132	C;G;T	127;129;129	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3526	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2947	118.5	1	SNP	p	R87W	0	.	.	259	261	CGT	589	591	CGT	130;130;132	C;G;T	127;129;129	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3526	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2947	118.5	1	SNP	p	R87I	0	.	.	259	261	CGT	589	591	CGT	130;130;132	C;G;T	127;129;129	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3526	parC	2304	2304	100.0	parC.l6.c17.ctg.1	2947	118.5	1	SNP	p	S88P	0	.	.	262	264	TCC	592	594	TCC	134;134;132	T;C;C	132;132;130	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3060	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2663	113.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1488	1490	GGC	162;158;158	G;G;C	157;149;152	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1232	1234	GCA	146;146;149	G;C;A	142;140;145	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1235	1237	ATC	151;148;151	A;T;C	146;143;145	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1247	1249	GTG	153;153;151	G;T;G	149;146;149	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1247	1249	GTG	153;153;151	G;T;G	149;146;149	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1751	1753	ACC	130;132;133	A,G;C;C	126,1;129;131	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1805	1807	GCG	147;146;146	G;C;G,A,C	138;131;137,1,1	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1805	1807	GCG	147;146;146	G;C;G,A,C	138;131;137,1,1	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1928	1930	AGC	121;120;120	A;G;C	117;117;115	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1937	1939	GGC	115;114;113	G;G;C,G	111;111;107,1	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2934	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2464	117.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1955	1957	CCG	85;89;87	C;C;G,C	82;89;82,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4320	ponA	2397	2397	99.92	ponA.l15.c30.ctg.1	3271	130.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1766	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1879	92.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	592	592	C	112	C,G	102,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2020	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1570	127.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	440	442	GAA	141;141;140	G;A;A	138;139;137	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2020	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1570	127.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	851	853	TCA	138;138;136	T;C;A	135;134;134	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2020	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1570	127.4	0	.	p	.	0	A218V	NONSYN	652	654	GCC	980	982	GTC	160;159;159	G;T,G;C	153;152,1;155	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2020	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1570	127.4	0	.	p	.	0	F222S	NONSYN	664	666	TTT	992	994	TCT	165;164;165	T;C;T	162;164;164	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2020	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1570	127.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1310	1312	GCA	152;151;154	G,T;C;A	150,1;146;151	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2020	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1570	127.4	1	SNP	p	G120K	1	.	.	358	360	AAG	686	688	AAG	146;143;144	A;A;G	144;140;136	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2020	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1570	127.4	1	SNP	p	A121D	1	.	.	361	363	GAC	689	691	GAC	144;142;142	G;A;C	140;137;141	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2020	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1570	127.4	1	SNP	p	D121N	0	.	.	361	363	GAC	689	691	GAC	144;142;142	G;A;C	140;137;141	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7256	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4837	148.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	786	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	913	84.6	1	SNP	p	V57M	1	.	.	169	171	ATG	455	457	ATG	157;158;156	A;T;G	152;153;151	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
